Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
MELBOURNE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Percheron Therapeutics Limited (ASX: PER | US OTC: PERCF), based in Melbourne, Australia and focused on the development of novel therapies for oncology and rare diseases, today announced that Dr James Garner, CEO and Managing Director, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.
DATE: September 18th
TIME: 4:00 PM ET
LINK: REGISTER HERE
Available for 1x1 meetings: September 18 to September 23, 2025. Sign up here.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- On 26 June 2025 Percheron signed an exclusive worldwide licensing agreement for its lead asset HMBD-002, a first in class immune-oncology asset
- HMBD-002 has the potential to target both solid tumours and haematological malignancies
- Phase 1 study has been completed in the US showing favourable safety profile and potential indication of efficacy
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
